These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26187708)

  • 1. Consensus Document on Prevention and Treatment of Tuberculosis in Patients for Biological Treatment.
    Mir Viladrich I; Daudén Tello E; Solano-López G; López Longo FJ; Taxonera Samso C; Sánchez Martínez P; Martínez Lacasa X; García Gasalla M; Dorca Sargatal J; Arias-Guillén M; García García JM
    Arch Bronconeumol; 2016 Jan; 52(1):36-45. PubMed ID: 26187708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations.
    Iannone F; Cantini F; Lapadula G
    J Rheumatol Suppl; 2014 May; 91():41-6. PubMed ID: 24788999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for Latent Tuberculosis Infection in Patients who are Candidate for Biological Therapies in Spain? A Multidisciplinary Survey.
    Quirós S; de la Rosa D; Uranga A; Madero R; Amaro R; Bruguera N; García JA; Gómez C; Iturbe D; Lera R; Luque L; Martínez AJ; Mínguez P; Navarro A; Sánchez G; Suárez-Cuartín G
    Arch Bronconeumol (Engl Ed); 2018 Oct; 54(10):510-517. PubMed ID: 29941293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.
    Papay P; Primas C; Eser A; Novacek G; Winkler S; Frantal S; Angelberger S; Mikulits A; Dejaco C; Kazemi-Shirazi L; Vogelsang H; Reinisch W
    Aliment Pharmacol Ther; 2012 Nov; 36(9):858-65. PubMed ID: 22978645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and therapeutic approach of latent tuberculosis infection.
    Domínguez J; Latorre I; Santin M
    Enferm Infecc Microbiol Clin (Engl Ed); 2018 May; 36(5):302-311. PubMed ID: 29295754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient.
    Rodríguez-Jiménez P; Mir-Viladrich I; Chicharro P; Solano-López G; López-Longo FJ; Taxonera C; Sánchez-Martínez P; Martínez-Lacasa X; García-Gasalla M; Dorca J; Arias-Guillén M; García-García JM; Dauden E
    Actas Dermosifiliogr (Engl Ed); 2018 Sep; 109(7):584-601. PubMed ID: 29871738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
    Hsia EC; Schluger N; Cush JJ; Chaisson RE; Matteson EL; Xu S; Beutler A; Doyle MK; Hsu B; Rahman MU
    Arthritis Rheum; 2012 Jul; 64(7):2068-77. PubMed ID: 22238071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approach to Latent Tuberculosis Infection Screening Before Biologic Therapy in IBD Patients: PPD or IGRA?
    Hashash JG; Abou Fadel C; Hosni M; Hassoun L; Kanafani Z; Regueiro MD
    Inflamm Bowel Dis; 2020 Aug; 26(9):1315-1318. PubMed ID: 32483628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-γ release assay results.
    Costantino F; de Carvalho Bittencourt M; Rat AC; Loeuille D; Dintinger H; Béné MC; Faure G; Chary-Valckenaere I
    J Rheumatol; 2013 Dec; 40(12):1986-93. PubMed ID: 24085550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidelines for the use of interferon-γ release assays in the diagnosis of tuberculosis infection.
    Santin M; García-García JM; Domínguez J;
    Enferm Infecc Microbiol Clin; 2016 May; 34(5):303.e1-13. PubMed ID: 26917222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of the tuberculin skin test and interferon-γ release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches.
    Goletti D; Sanduzzi A; Delogu G
    J Rheumatol Suppl; 2014 May; 91():24-31. PubMed ID: 24788997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time for a change? Updated guidelines using interferon gamma release assays for detection of latent tuberculosis infection in the office setting.
    Kardos M; Kimball AB
    J Am Acad Dermatol; 2012 Jan; 66(1):148-52. PubMed ID: 22177633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the use of the interferon-γ response to Mycobacterium tuberculosis-specific antigens in patients with psoriasis prior to antitumour necrosis factor-α therapy: a prospective head-to-head cross-sectional study.
    Martyn-Simmons CL; Mee JB; Kirkham BW; Groves RW; Milburn HJ
    Br J Dermatol; 2013 May; 168(5):1012-8. PubMed ID: 23278714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.
    Mariette X; Baron G; Tubach F; Lioté F; Combe B; Miceli-Richard C; Flipo RM; Goupille P; Allez M; Salmon D; Emilie D; Carcelain G; Ravaud P
    Ann Rheum Dis; 2012 Nov; 71(11):1783-90. PubMed ID: 22258485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents.
    Kim JH; Won S; Choi CB; Sung YK; Song GG; Bae SC
    Int J Rheum Dis; 2015 Mar; 18(3):315-22. PubMed ID: 25351815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latent tuberculosis infection--Revisiting and revising concepts.
    Salgame P; Geadas C; Collins L; Jones-López E; Ellner JJ
    Tuberculosis (Edinb); 2015 Jul; 95(4):373-84. PubMed ID: 26038289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
    Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
    J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on screening and treatment of tuberculosis infection in patients with inflammatory bowel disease.
    Riestra S; Taxonera C; Zabana Y; Carpio D; Beltrán B; Mañosa M; Gutiérrez A; Barreiro-de Acosta M
    Gastroenterol Hepatol; 2021 Jan; 44(1):51-66. PubMed ID: 32828562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions.
    Kleinert S; Tony HP; Krueger K; Detert J; Mielke F; Rockwitz K; Schwenke R; Burmester GR; Diel R; Feuchtenberger M; Kneitz C
    Ann Rheum Dis; 2012 Nov; 71(11):1791-5. PubMed ID: 22586160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can ELISpot replace the tuberculin skin test for latent tuberculosis?
    Greveson K
    Br J Nurs; 2009 Nov 12-25; 18(20):1248-54. PubMed ID: 20081663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.